Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter

Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter

Modified vaccinia virus Ankara (MVA)-vectored vaccines against malaria, influenza, tuberculosis and recently Ebola virus are in clinical development. Although this vector is safe and immunogenic in humans, efforts remain on-going to enhance immunogenicity through various approaches such as using str...

Podrobná bibliografie
Hlavní autoři:	Alharbi, N, Spencer, A, Salman, A, Tully, C, Chinnakannan, S, Lambe, T, Yamaguchi, Y, Morris, S, Orubu, T, Draper, S, Hill, A, Gilbert, S
Médium:	Journal article
Vydáno:	Elsevier 2015

Podobné jednotky

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.
Autor: Orubu, T, a další
Vydáno: (2012)

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.
Autor: Toritse Orubu, a další
Vydáno: (2012-01-01)

Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.
Autor: Naif Khalaf Alharbi, a další
Vydáno: (2015-01-01)

Generation of multivalent recombinant MVA vaccines for malaria
Autor: Orubu, T
Vydáno: (2012)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
Autor: Antrobus, R, a další
Vydáno: (2012)

Poxviral promoters for improving the immunogenicity of MVA delivered vaccines
Autor: Naif Khalaf Alharbi
Vydáno: (2019-01-01)

Novel bivalent viral-vectored vaccines induce potent humoral and cellular immune responses conferring protection against stringent influenza a virus challenge
Autor: Tully, C, a další
Vydáno: (2017)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Autor: Sheehy, S, a další
Vydáno: (2012)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Autor: Green, C, a další
Vydáno: (2015)

Viral vectors as vaccine platforms: from immunogenicity to impact
Autor: Ewer (nee Russell), K, a další
Vydáno: (2016)

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
Autor: Berthoud, T, a další
Vydáno: (2011)

Uncovering the mechanisms of adenovirus vector immunogenicity
Autor: Dicks, M, a další
Vydáno: (2013)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
Autor: Richard D Antrobus, a další
Vydáno: (2012-01-01)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Autor: Naif Khalaf Alharbi, a další
Vydáno: (2022-08-01)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Autor: Alharbi, N, a další
Vydáno: (2017)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Autor: Brookes, R, a další
Vydáno: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Autor: Roger H Brookes, a další
Vydáno: (2008-08-01)

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.
Autor: Moore, A, a další
Vydáno: (2005)

MAIT cell activation augments adenovirus vector vaccine immunogenicity
Autor: Provine, N, a další
Vydáno: (2021)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
Autor: Betts, G, a další
Vydáno: (2012)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Autor: Rowland, R, a další
Vydáno: (2012)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
Autor: Roger H. Brookes, a další
Vydáno: (2011-01-01)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
Autor: Rampling, T, a další
Vydáno: (2015)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
Autor: Dicks, M, a další
Vydáno: (2011)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
Autor: Alharbi, N, a další
Vydáno: (2015)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Autor: Howles, S, a další
Vydáno: (2010)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Autor: Imoukhuede, E, a další
Vydáno: (2006)

Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
Autor: Lambe, T, a další
Vydáno: (2013)

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity to bacterial, viral and parasitic antigens: increased durable cellular immunity with reduced immunodominance
Autor: Moore, A, a další
Vydáno: (2005)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
Autor: Bliss, C, a další
Vydáno: (2016)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
Autor: Ramil R. Mintaev, a další
Vydáno: (2023-04-01)

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
Autor: Dicks, M, a další
Vydáno: (2012)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
Autor: Gareth Betts, a další
Vydáno: (2012-01-01)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
Autor: Sheehy, S, a další
Vydáno: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Autor: Sheehy, S, a další
Vydáno: (2011)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
Autor: Borthwick, N, a další
Vydáno: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
Autor: Borthwick NJ, a další
Vydáno: (2012-09-01)

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
Autor: Lillie, P, a další
Vydáno: (2012)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
Autor: Ewer (nee Russell), K, a další
Vydáno: (2017)

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.
Autor: Busquets, N, a další
Vydáno: (2014)